Investigation of the prevalence of toxoplasmosis in patients with malignancies, southwest of Iran

Document Type : Original Articles

Authors

1 Thalassemia &Hemoglobinopathy Research center, Health research institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

2 Department of Biology, Izeh branch, Islamic Azad University, Izeh, Iran

3 Thalassemia &Hemoglobinopathy Research center, research institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

4 izmir ekonomi university, Faculti of medical science,izmir, Turkey.

5 Clinical research development unit, Bahar hospital, Shahroud university of Medical Sciences, Shahroud, Iran

6 Thalassemia &Hemoglobinopathy Research center, Health research institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

10.32592/ARI.2025.80.2.571

Abstract

Toxoplasmosis is a parasitic disease, that can affect humans, other warm-blooded animals, and cats. Cancer patients receiving chemotherapy, individuals with immunocompromised immune systems, AIDS patients, transplant recipiens, and hemodialysis patiens, are at a greater risk of contracting toxoplasmosis.
Due to the similarity of certain toxoplasmosis symptoms to those of cancer or chemotherapy-related problems, it is difficult to establish the existence of toxoplasmosis symptoms, For this reason, one of the ways to prove this infection is the ELISA test and determining the amount of antibodies in the patient.
Blood was drawn from 90 cancer patients who had been admitted to the hospital and were at various stages of chemotherapy. The anti-toxoplasma antibody titer was then determined using the ELISA method, and the data were analyzed using SPSS version 23 software.
In this study, 50(55.6%) were women and 40(44.4%) were men, all samples were negative for IgM antibody titer while 50 samples(55.6%) were positive for IgG antibodies. In patients with positive tests, the most common clinical symptoms were lethargy and anorexia. Although anti-toxoplasma IgG antibodies were more in men than women, no significant difference was seen between gender and infection. It was also observed that anti-toxoplasma IgG antibodies were higher in people who had a history of chemotherapy compared to people with malignancies without such a history, the level of anti-toxoplasma IgG in malignant patients hospitalized in this hospital was high, but statistical analysis showed a significant difference between the prevalence of toxoplasma and the type of cancer.
Cancer patients are at great risk of developing severe toxoplasmosis and its consequences due to the high incidence of T. gondii. Therefore, Oncologists should view this serious medical condition as requiring immediate attention.

Keywords

Main Subjects

References

  1. Foroutan-Rad M, Majidiani H, Dalvand S, Daryani A, Kooti W, Saki J, Hedayati-Rad F, Ahmadpour E. Toxoplasmosis in blood donors: a systematic review and meta-analysis. Transfusion medicine reviews. 2016 Jul 1;30(3):116-22.
  2. Seyedtabaei S.J., Arab Mazar.Z., Yadgarnia.D., Rajaian.S., Fallahi.S. Investigation of the frequency of IgM and IgG of Toxoplasma gondii in selected hemodialysis centers of Tehran in 2015. Yafteh, 2017: 78-84 [In persian].
  3. Halonen SK, Weiss LM. Toxoplasmosis. Handb Clin Neurol. 2013;114:125-45. doi: 10.1016/B978-0-444-53490-3.00008-X. PMID: 23829904; PMCID: PMC4157368.
  4. de Almeida Aloise D, Coura-Vital W, Carneiro M, Rodrigues MV, da Silva Toscano GA, da Silva RB, de Andrade Neto VF, Wagner R, Vitor A. Seroprevalence and risk factors for human toxoplasmosis in northeastern Brazil. Rev Patol Trop Trop Pathol. 2017;46(4):307-20.
  5. Tait ED, Hunter CA. Advances in understanding immunity to Toxoplasma gondii. Memorias do Instituto Oswaldo Cruz. 2009;104:201-10.
  6. Arefkhah N, Sarkari B, Afrashteh M, Rezaei Z, Dehghani M. Toxoplasma gondii: the prevalence and risk factors in HIV-infected patients in Fars province, southern Iran. Iran Red Crescent Med J. 2018 Jun 1;20(6):e66521.
  7. Ahmadpour E, Daryani A, Sharif M, Sarvi S, Aarabi M, Mizani A, Rahimi MT, Shokri A. Toxoplasmosis in immunocompromised patients in Iran: a systematic review and meta-analysis. J Infect Dev Ctries. 2014 Dec 15;8(12):1503-10. doi: 10.3855/jidc.4796. PMID: 25500647.
  8. Edvinsson B, Jalal S, Nord CE, Pedersen BS, Evengård B; ECSMID Study Group on Toxoplasmosis. DNA extraction and PCR assays for detection of Toxoplasma gondii. APMIS. 2004 Jun;112(6):342-8. doi: 10.1111/j.1600-0463.2004.apm1120604.x. PMID: 15511271.
  9. Sarkari B, Shafiei R, Zare M, Sohrabpour S, Kasraian L. Seroprevalence and molecular diagnosis of Toxoplasma gondii infection among blood donors in southern Iran. J Infect Dev Ctries. 2014 Apr 15;8(4):543-7. doi: 10.3855/jidc.3831. PMID: 24727522.
  10. Maciel E, Siqueira I, Queiroz AC, Melo A. Toxoplasma gondii myelitis in a patient with adult T-cell leukemia-lymphoma. Arq Neuropsiquiatr. 2000 Dec;58(4):1107-9. doi: 10.1590/s0004-282x2000000600019. PMID: 11105079.
  11. Filisetti D, Candolfi E. Immune response to Toxoplasma gondii. Ann Ist Super Sanita. 2004;40(1):71-80. PMID: 15269455.
  12. Israelski DM1, Remington   JS   (1993)   Toxoplasmosis   in  patients with cancer. Clin Infect Dis 17 Suppl 2:423-435.
  13. Hosseini-Safa A, Shojaee S, Salami SA, Mohebali M, Hantoushzadeh S, Mousavi P, Dehghan Manshadi SA, Keshavarz Valian H. Development of High Resolution Melting Analysis as a Diagnostic Tool for Molecular Detection of ToxoplasmaInfection in Pregnant Women and HIV Positive Cases. Iran J Public Health. 2020 Oct;49(10):1983-1991. doi: 10.18502/ijph.v49i10.4704. PMID: 33346240; PMCID: PMC7719646.
  14. Mostafa NE, Hamed EF, Rashed HE, Mohamed SY, Abdelgawad MS, Elasbali AM. The relationship between toxoplasmosis and different types of human tumors. The Journal of Infection in Developing Countries. 2018 Feb 28;12(02):137-41.
  15. Yazar S, Yaman O, Eser B, Altuntas F, Kurnaz F, Sahin I, (2004) Investigation of anti-Toxoplasma gondii antibodies in patients with neoplasia. J Med Microbiol 53: 1183–1186.
  16. Zhou N, Zhang XY, Li YX, Wang L, Wang LL, Cong W. Seroprevalence and risk factors of Toxoplasma gondii infection in oral cancer patients in China: a case–control prospective study. Epidemiol Infect. 2018;146:1891-5. doi: 10.1017/S0950268818001978.
  17. Abdel Malek R, Wassef R, Rizk E, Sabry H, Tadros N, Boghdady A. Toxoplasmosis an Overlooked Disease: Seroprevalence in Cancer Patients. Asian Pac J Cancer Prev. 2018;19(7):1987-91.

    18. Shoukat T, Awan UA, Mahmood T, Afzal MS, Wasif S, Ahmed H, Cao J. Epidemiology of Toxoplasmosis among the Pakistani Population: A Systematic Review and Meta-Analysis. Pathogens. 2022 Jun 10;11(6):675.

  18. Kalantari N, Rezanejad J, Tamadoni A, Ghaffari S, Alipour J, Bayani M. Association between Toxoplasma gondii exposure and paediatrics haematological malignancies: a case–control study. Epidemiology & Infection.
  19. Karin M, Greten FR (2005) NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev. Immunol 5:749–759.
  20. Ewald PW. An evolutionary perspective on parasitism as a cause of cancer. Adv Parasitol. 2009;68:21-43. doi: 10.1016/S0065-308X(08)00602-7. PMID: 19289189.
  21. Cong W, Liu GH, Meng QF, Dong W, Qin SY, Zhang FK, Zhang XY, Wang XY, Qian AD, Zhu XQ (2015) Toxoplasma gondii infection in cancer patients: prevalence, risk factors, genotypes and association with clinical diagnosis. Cancer Lett , 359: 307-313.
  22. Sadr S, Ghiassi S, Lotfalizadeh N, Simab PA, Hajjafari A, Borji H. Antitumor Mechanisms of Molecules Secreted by Trypanosoma cruziin Colon and Breast Cancer: A Review. Anticancer Agents Med Chem. 2023;23(15):1710-1721. doi: 10.2174/1871520623666230529141544. PMID: 37254546.
  23. Lotfalizadeh N, Sadr S, Morovati S, Lotfalizadeh M, Hajjafari A, Borji H. A potential cure for tumor-associated immunosuppression by Toxoplasma gondii. Cancer Rep (Hoboken). 2024 Feb;7(2):e1963. doi: 10.1002/cnr2.1963. Epub 2023 Dec 18. PMID: 38109851; PMCID: PMC10850000.
  24. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell (2017) 168(4):707–23. 10.1016/j.cell.2017.01.017
  25. Sadr S, Borji H. Echinococcus granulosus as a promising therapeutic agent against triplenegative breast cancer. Current Cancer Therapy Reviews. 2023 Nov 1;19(4):292-7.
  26. Sadr S, Yousefsani Z, Simab PA, Alizadeh AJ, Lotfalizadeh N, Borji H. Trichinella spiralis as a potential antitumor agent: An update. World's Veterinary Journal. 2023 Mar 25;13(1):65-74.
  27. Oikonomopoulou K, Yu H, Wang Z, Vasiliou SK, Brinc D, Christofi G, et al. Association between Echinococcus granulosusinfection and cancer risk—a pilot study in Cyprus. Clin Chem Lab Med(2016) 54(12):1955–61. 10.1515/cclm-2016-0125.
  28. Yong W, Heath D, Savage T. Possible antigenic similarity between pulmonary carcinoma and cysts of Echinococcus granulosus. Br Med J(1979) 1(6176):1463. 10.1136/bmj.1.6176.1463-a
Archives of Razi Institute
Volume 80, Issue 2
March and April 2025
Pages 571-577

Files

Share

How to cite

Statistics